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A B S T R A C T
In recent years there is an increasing interest in the pulmonary delivery of large cohesive powder doses, i.e.
drugs with a low potency such as antibiotics or drugs with a high potency that need a substantial fraction of
excipient(s) such as vaccines stabilized in sugar glasses. The pulmonary delivery of high powder doses comes
with unique challenges. For low potency drugs, the use of excipients should be minimized to limit the powder
mass to be inhaled as much as possible. To achieve this objective the inhaler design should be adapted to the
properties of the API in order to achieve a compatible combination of the drug formulation and inhaler device.
The inhaler should have an appropriate powder dosing principle for which preﬁlled compartments seem most
appropriate. The drug formulation should not only allow for accurate ﬁlling of these compartments but also
enable eﬃcient compartment emptying during inhalation. The dispersion principle must have the capacity to
disperse considerable amounts of powder in a short time frame that allows the powder to reach the deep lung.
Last, but not least, the inhaler should be simple and intuitive in use, be cost-eﬀective and exhibit accurate and
consistent, preferably patient independent, pulmonary delivery performance.
1. Introduction
Pulmonary administration of low dose active pharmaceutical in-
gredients (APIs) as dry powders has been used widely to treat various
diseases for about 50 years. Their use is aimed primarily at the treat-
ment of asthma and chronic obstructive pulmonary disease (COPD) and
the drugs involved are mostly given in a dose range of 6
(formoterol)–500 μg (ﬂuticasone propionate) (Smith and Parry-Billings,
2003). In recent years an increasing interest has developed in the de-
livery of low potency drugs like antibiotics via the pulmonary route.
These APIs often have to be administered in much higher doses to
achieve their therapeutic eﬀect. Doses for such drugs are in the milli-
gram-range without excipient(s) and they may even extend to the gram-
range, as shown in Table 1. An increasing interest in pulmonary de-
livery also exists for high potency, low dose drugs that require a notable
amount of excipient in the respirable particles. This too may result in a
high powder dose, and therefore, in similar challenges regarding their
formulation and dispersion as the low potency, high dose drugs. As
such, both types of drug are regarded as ‘high (powder) dose drugs’ in
this review. This is further elaborated on in Section 2, where a deﬁni-
tion of high powder doses is presented.
The increasing interest in the pulmonary delivery of high dose drugs
is the result of signiﬁcant potential advantages of this route of admin-
istration compared to the oral or parenteral routes. These advantages
include a targeted delivery to the lungs with lower systemic side eﬀects
at higher local concentrations, which increases the therapeutic eﬃcacy
as a result. In addition, a faster response can be obtained both locally
and systemically. Furthermore, no or only limited ﬁrst pass metabolism,
the capacity for large molecules to be absorbed in high doses in the
lower respiratory tract, and the ability to trigger a local immunological
response which can be beneﬁcial for vaccines are other advantages of
pulmonary delivery (Hoppentocht et al., 2014a; Labiris and Dolovich,
2003; Tonnis et al., 2013). Finally, macrophages in the lungs may be
targeted, which can harbor infectious bacteria such as Mycobacterium
tuberculosis (Patel et al., 2015).
High dose inhaled antibiotics like colistin and tobramycin dry
powder products are already on the market, and further research is
performed on amikacin, kanamycin, gentamycin and isoniazid,
amongst others. The colistin and tobramycin products are used in the
treatment of cystic ﬁbrosis patients whereas the other antibiotics are
investigated for use in diseases such as tuberculosis (TB) and bronch-
iectasis (Davis et al., 2007; Eldon et al., 2008; Luyt et al., 2009; Sacks
et al., 2001; Turner et al., 1998). For anti-fungal compounds multiple
dry powder formulations have been described. For instance, ampho-
tericin B and voriconazole have been successfully formulated and tested
in vitro, with animal studies being planned for both formulations (Arora
et al., 2015; Shah and Misra, 2004). However, not only antimicrobial
drugs have been taken into consideration. Also liposomal tacrolimus
and cyclodextrin complexes of cyclosporin A have been investigated as
dry powder for the prevention of organ rejection after lung transplants
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(Chougule et al., 2007; Matilainen et al., 2006). Cyclosporin A has also
been described for the treatment of asthma, COPD, cystic ﬁbrosis and
lung cancers (Cun et al., 2015). Other locally acting drugs for which
high dose pulmonary administration may be useful include che-
motherapeutic drugs in lung cancer (Zarogoulidis et al., 2012) and
drugs against pulmonary arterial hypertension (Ghanbarzadeh et al.,
2016; Wang et al., 2016).
For systemically acting drugs, the fast systemic absorption that may
be achieved via the pulmonary route is for instance beneﬁcial in the
treatment of oﬀ periods in Parkinson’s disease with levodopa or the
acute treatment of agitation with loxapine (Keating, 2013; Luinstra
et al., 2015). In some cases the low metabolic activity of the pulmonary
route or its permeability to large molecules of several kilodaltons in size
(such as small proteins) are of particular interest. Examples of the latter
include the systemic delivery of calcitonin for calcium homeostasis and
bone remodeling, low molecular weight heparin against deep vein
thrombosis, and insulin for type 1 and type 2 diabetes. (Bai and Ahsan,
2009; Barnett, 2004; Yang et al., 2012).
Many of the new drugs taken recently into development are bio-
pharmaceuticals and most examples within this new class of drugs are
large-molecule compounds, e.g. peptides proteins, antibodies and nu-
cleic acids (Agrawal, 2015). The majority of these new compounds are
investigated for cancer therapy or treatment of neurological diseases,
infections and immunological disorders. But also compounds against
cardiovascular disease, mental health disorders, diabetes and HIV/AIDS
are in various phases of clinical studies. Most of them need to act sys-
temically and one of the greatest challenges is to get them into the
blood stream as large biopharmaceutical molecules cannot eﬀectively
be absorbed by the lining of the human intestines (Renukuntla et al.,
2013). Typically, their bioavailability after oral administration is less
than 1–2% and pulmonary delivery may bypass this problem. A ple-
thora of devices for drug delivery to the respiratory tract is available
and they can be divided into nebulizers, metered dose inhalers (MDIs)
and dry powder inhalers (DPIs). However, most of the currently mar-
keted inhalation devices are not designed for high doses and are,
therefore, not suitable for this purpose. For instance, none of the cur-
rently available MDIs can deliver the required high drug amounts as
their metering chambers generally have a maximum volume of around
100 µl (Stein et al., 2014). Besides, many biopharmaceuticals are not
stable in either solution or suspension, and as such it should be avoided
to formulate them in liquids (Hinrichs et al., 2001; Wang et al., 2012).
Although high doses can be dispersed with nebulizers, these devices
have many disadvantages as well. APIs are in solution or have to be
reconstituted in water before use, which either requires a cold chain to
keep them stable or clean water, respectively (Hoppentocht et al.,
2014b). Furthermore, high shear forces during droplet formation may
cause stability problems for biopharmaceuticals (Cun et al., 2015;
Khatri et al., 2001). Other disadvantages of nebulizers are the long
administration time and the need to clean them after each adminis-
tration and/or disinfect them on a regular basis. Most nebulizers are
voluminous and need electricity or pressurized air for their operation
which limits the mobility of the patient (de Boer and Hagedoorn, 2015;
Hoppentocht et al., 2014a; Tonnis et al., 2013). Lastly the residual li-
quid left after administration can be a problem. This residue can
amount up to 30% of the total volume and, as a result of evaporation,
an even higher percentage of the total drug dose. This increases costs,
which can be a signiﬁcant disadvantage for expensive APIs like bio-
pharmaceuticals (Tonnis et al., 2013).
With dry powder inhalers (DPIs) several of the problems mentioned
above may be omitted. The dose is not necessarily limited by the size of
the dose compartment and many APIs are stable in the dry state or can
be stabilized in excipient matrices like insulin or trehalose.
Consequently, powder formulations for the drugs do generally not need
a cold chain for transport and storage (Hinrichs et al., 2001;
Hoppentocht et al., 2014a; Parumasivam et al., 2016). Moreover, they
allow for fast administration, require limited maintenance or cleaning,
they can be made disposable (e.g. for single use) and many show a low
inhaler retention. Commercially successful DPI developments for pul-
monary administration of high dose drugs are as of yet scarce however.
The scarcity in high dose DPI developments is reﬂected by the lack
of studies and literature reviews on this subject. It might be explained
by the challenges encountered in achieving a good tuning between DPI
design and high dose formulation properties. Generally, high dose
formulations are very cohesive and diﬃcult to measure and disperse
reproducibly into suitable aerosols for inhalation. This may put high
demands on the inhaler dose (measuring) and dispersion principles.
This review aims to aid in that regard by giving an extensive overview
of the current state of the art concerning formulation techniques and
devices currently in use. It also presents considerations for DPI design
and what knowledge gaps remain for the further improvement of high
dose dry powder aerosol delivery.
2. Diﬀerences between low and high dose delivery
For a better understanding of the inhaler requirements for high dose
powder administration to the respiratory tract a comparison with low
dose delivery may be helpful. It all starts with the deﬁnitions for high
and low doses and to the authors’ best knowledge no unambiguous
deﬁnition has yet been given in literature as to what constitutes low and
high pulmonary doses. Low dose drugs for inhalation in the microgram-
range (< 1mg) are usually mixed with much coarser lactose carrier
particles to improve their dose reproducibility. During the mixing
process, the micronized drug particles adhere to the surface of the
carrier particles, thereby constituting so-called adhesive mixtures, also
named interactive or ordered mixtures (Hersey, 1975; Staniforth,
1987). The mass of adhesive mixture dispersed by currently marketed
inhalers is usually in the range between 10 and 25mg. There is a limit
to the drug quantity that can be processed in adhesive mixtures. For the
sake of content uniformity and stability, they can contain maximally
Table 1
Several APIs that may beneﬁt from high dose pulmonary administration. The
doses reported in DPIs, the doses used in studies, either with dry powder (dp) or
nebulized (neb), and the estimated dry powder dose required for these APIs are
given. When a dose was reported based on the patients’ weight, the average
weight of a European, 70.8 kg, was used to calculate the total dose. A conver-
sion factor of 2.5 was used to calculate the expected dry powder dose required
from the nebulized doses. This factor was based on the diﬀerence in dose be-
tween nebulized and dry powder formulations of tobramycin and colistin.
Estimated dry powder doses from nebulization were placed in ranges of
5–50mg, 50–100mg. 100–200mg, 200–500mg, 500–1000mg, and
1000–2000mg. References included: (Ahmed et al., 1999; Andersen et al.,
2017; Corcoran et al., 2014; Davis et al., 2007; Ehrmann et al., 2008; Eldon
et al., 2008; Groves et al., 2010; Hagedoorn et al., 2017; Hayes et al., 2010;
Keating, 2013; Konstan et al., 2011; LeWitt et al., 2016; Lipp et al., 2016;
Luinstra et al., 2015; Luyt et al., 2009; Quon et al., 2014; Sacks et al., 2001;








tobramycin (TOBI) 28mg 112mg dp 112mg
colistin (colobreathe) 125mg 125mg dp 125mg
colistin (Twincer) 55mg 55mg dp 55mg
loxapine 5–10mg 5–10mg dp 5–10mg
levodopa 40mg 35–50mg dp 35–50mg
voriconazole 20mg 40mg neb 5–50mg
amikacin 400–4248mg neb 100–2000mg
kanamycin 80–750mg neb 100–500mg
gentamycin 80mg neb 5–50mg
amphotericin B 25–50mg neb 5–50mg
tacrolimus 20mg neb 5–50mg
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around 5–10% of drug, depending on the type of carrier particles used
(Grasmeijer et al., 2015). The amount of drug in 25mg adhesive mix-
ture is, therefore, maximally 2.5mg. At higher drug concentrations,
multiple drug layers on the carrier surface and drug pellets without
carrier nucleus may be formed, which are mechanically unstable and
negatively aﬀect dose reproducibility. Practically, drug concentrations
in marketed products are limited to the range between 0,1 and 4% to
minimize the risk of dose inconsistency (Grasmeijer et al., 2013).
On the basis of the previous reasoning, one should consider inhaled
drug doses larger than 2.5 mg as high. Drug doses of 2.5 mg and more
should not be administered as an adhesive mixture, because it would
imply the inhalation of 62.5mg powder (for a 4% mixture) or even
considerably more (for mixtures with less than 4% drug or for larger
drug doses). Considering the size fraction of the carrier particles this
would result in severe deposition of carrier particles and drug bound to
these particles in the throat where cough reactions are induced and the
drug may cause adverse local side eﬀects. It would also require multiple
inhalations for a single dose which is a burden for the patient and re-
sults in a demotivation for adhering to the therapy.
Micronized drugs in the absence of freely ﬂowing carrier particles
have basically diﬀerent properties compared to adhesive mixtures. By
not being attached to a carrier surface the intrinsic properties of the
drug particles govern the powder behavior. Powders consisting of pure
micronized particles for inhalation have very poor ﬂow properties and
tend to form large lumps without further processing. This aﬀects the
dose measuring into or by the inhaler, the drug entrainment from the
dose (measuring) compartment, the aerosolization and dispersion per-
formance and the drug retention in the inhaler. To large extent the
diﬀerence in properties compared to those of adhesive mixtures is the
same for pure drug particles and drug-excipient composite particles as
obtained for instance from spray drying. It is primarily the micronized
state that determines the high co- and adhesiveness of the powder.
Therefore, low dose drugs administered in quantities smaller than
2.5 mg that need for instance stabilization with an excess of sugar
glasses (e.g. biopharmaceuticals) or are co-processed with large
amounts of excipients for other reasons should be considered as high
dose drugs too in this respect. It is rather the type of formulation (ad-
hesive mixture or micronized powder and soft pellets respectively) than
the amount of drug in the formulation that determines what a high dose
is. The properties of high dose drugs are also rather independent of
further processing of the drug particles. For instance, pelletization can
improve the ﬂow properties and the aerosolization behavior (entrain-
ment), but dispersion performance and retention behavior remain lar-
gely the same in the same type of inhaler. Most high dose drugs or drug
formulations, particularly those prepared by spray drying, are often
also highly hygroscopic. This further increases the co- and adhesiveness
of the powders. Some behavior aspects of inhalation powders are in-
trinsic to the high masses or volumes in which they are given. Large
cohesive powder quantities can be diﬃcult to entrain from the dose
compartment, overload dispersion principles and build up thick powder
layers on various inhaler parts, particularly when the powders are not
only highly adhesive, but also highly compactible.
Because of all these diﬀerences, diﬀerent dispersion principles may
be needed to convert carrier based adhesive mixtures and cohesive
powder masses eﬀectively into suitable aerosols for inhalation. The
drug-to-carrier interaction forces in adhesive mixtures are generally
high by the action of the mixing forces during preparation. This may
result in ﬁrm pressing of the drug particles against the carrier surface as
mixing times are often very long to achieve the desired content uni-
formity of the blend. Drug particles may also ﬁnd shelter in carrier
surface irregularities from the separation forces of the drag and lift type
(de Boer et al., 2012; Grasmeijer et al., 2015). Agglomerates of cohesive
micronized powders mostly have porosities over 70–80% (Trofast et al.,
2002). This means that the average coordination number in such ag-
glomerates (number of contact points per particle) is very low and that
there exists an abundance of free space for particle re-arrangement
under the inﬂuence of external forces (Fig. 1A). These diﬀerences seem
to make inertial dispersion or separation forces, as from particle colli-
sions onto the inner walls of circulation chambers (Fig. 1B), more ap-
propriate for adhesive mixtures. In contrast, internal shear, as for in-
stance in turbulent or impinging air streams, may be more eﬀective for
cohesive agglomerates (Fig. 1C). As a result of all these diﬀerences
compared to adhesive mixtures for low dose drugs, the pulmonary
administration of high dose drugs gives rise to several speciﬁc chal-
lenges. They will be elaborated on in further detail in the following
sections of this manuscript.
3. The properties of particles and powders for inhalation
Powders for pulmonary administration have to fulﬁll several
Fig. 1. (A) Schematic two-dimensional presentation
of the void space in a powder with monosized par-
ticles having a porosity of 70%, showing the room
for particle re-arrangement upon the application of
an external force. (B) Densiﬁcation and compaction,
instead of dispersion, of the powder in Fig. 1A upon
collision of a pellet with an inhaler wall. (C) Dis-
persion of the same powder in two impinging air
ﬂows by internal shear, as in a circulation chamber
with tangential bypass channels.
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criteria. A basic requirement is that they should contain the drug par-
ticles in an aerodynamic size distribution between 1 and 5 μm (or even
more preferably between 1 and 3 μm) to obtain substantial central and
deep lung deposition (Labiris and Dolovich, 2003). Further require-
ments relate to good stability, maximal emission from the inhaler (i.e.
low retention) and adequate dispersion into the aerosol. Diﬀerent forces
govern the interaction between powder particles and, as such, the
dispersibility of the powder itself. They include electrostatic forces,
capillary forces and Van der Waals forces (Castellanos, 2005). The
physics of these forces have been described extensively elsewhere and
are not the scope of this manuscript (Castellanos, 2005; Visser, 1989).
Other forces can be present too but they play an ancillary role and are
deemed irrelevant for dry powder inhalation. Van der Waals forces are
generally the most dominant types of forces (by number) between
particles in dry powders (Castellanos, 2005). Van der Waals forces
depend on multiple factors. These are the chemical properties of the API
in question, and the physical properties of the particles prepared, in-
cluding their size and shape distribution, surface morphology (e.g.
rugosity, smoothness, purity), density, and water content. The physical
properties determine to large extent the magnitude of the Van der
Waals forces and modifying and/or controlling them is the rationale for
diﬀerent particle engineering techniques.
It has to be recognized that the interparticulate forces in micronized
powders (as for high dose drugs) can play a diﬀerent role than in ad-
hesive mixtures (for low dose drugs). This is primarily the result of the
diﬀerences in particle size distribution (PSD) between the carrier par-
ticles and drug particles. As already mentioned, the carriers in adhesive
mixtures for low dose drugs have mostly fair to good ﬂow properties. In
micronized powders cohesion forces (e.g. van der Waals forces, elec-
trostatic forces and capillary forces) are dominant over the forces of
gravity, which provides these powders their poor ﬂow properties and
strong agglomeration tendency. As a result, accurate dose measuring of
micronized powders may be much more problematic than that of ad-
hesive mixtures. The diﬀerences in powder properties, particularly the
diﬀerence in cohesiveness may, therefore, require basically diﬀerent
design solutions for high dose drug inhalers, as will be further explained
in Section 6.
Van der Waals (adhesion) forces can also exist between particles and
inhaler walls. They can lead to a high powder retention in the inhaler,
even when the emptying of the dose compartment is rather complete. In
addition to Van de Waals forces electrostatic forces may contribute to
inhaler retention, as the displacement of particles through the inhaler is
accompanied with repeated particle-wall contacts. Transfer of
Coulombic charge between particles and plastic parts of the inhaler
during moments of contact is the reason for cumulating opposite
charges between the powder and the inhaler walls. Particles can also be
charged in the air stream, particularly when the velocity diﬀerence
between the air and airborne particles is considerable. Furthermore,
particles can also be charged as a result of particle to particle collisions.
Also in this respect there exists a fundamental diﬀerence between low
and high dose formulations as will be elaborated in Section 6.
4. Techniques for the preparation of inhalation particles
Several techniques exist for the preparation of inhalation powders,
which diﬀer amongst other things in cost, scalability, compatibility
with the API and the way they enable rational particle engineering.
Milling has been used extensively as a top down approach to obtain
particles in the desired size range for inhalation but a considerable
knowledge gap remains where particle breakage is concerned (Shah
et al., 2017). As a result, milling is not particularly suited for the ra-
tional engineering of particles in terms of their shape, density or surface
properties. Nevertheless, milling can change the particle shape and
surface properties (Luner et al., 2012), which aﬀects the hydrophobicity
and ﬂowability of the powder particles (Feeley et al., 1998; Heng et al.,
2006). As explained in previous sections, this is especially relevant for
high dose powders which do not rely on coarse excipients for sa-
tisfactory ﬂowability and entrainment. An advantage of milling is that
it is cheap, reproducible and relatively easy to scale up. Diﬀerent mil-
ling techniques result in diﬀerent stresses on the particles, which may
result in diﬀerent surface energies. For example, Luner et al. compared
the wet and dry milling of succinic acid and sucrose. For both materials,
wet milling resulted in a higher surface energy than dry milling (Luner
et al., 2012). This may be relevant also when APIs are concerned that
are particularly sensitive to mechanical stress.
Another often-used technique to produce powders for pulmonary
administration is spray drying. Spray drying is a bottom-up approach
which is particularly suited for particle engineering. Particle en-
gineering via spray drying has been extensively reviewed elsewhere,
and, therefore, only a short overview will be given here (Vehring,
2008). Spray drying is a very well-scalable process which enables ﬁne
control over multiple process parameters and a wide range of particle
properties. Without the use of excipients, the density of the powder
particles and, as a result, that of the powder bulk can be changed. Of
course, for high dose drugs there is a limit to the powder volume that
can be dispersed and inhaled, which also puts a limit to the suitable
particle and powder density for each API. Furthermore, the particle size
distribution, surface morphology (smooth or corrugated), water content
and particle shape can be controlled. However, for thermolabile drugs
or drugs that are prone to sublimation, particle engineering options by
spray draying may be limited due to the restricted outlet temperature
range (Sibum et al., 2016). Additionally, spray dried particles are often
completely amorphous. Amorphous particles generally tend to be more
hygroscopic and have a higher surface energy, which makes them more
ad- and cohesive. Furthermore, the physico-chemical stability of
amorphous powders is generally lower than that of their crystalline
counterparts.
A relatively new method for the production of micron-sized powder
particles is supercritical ﬂuid technology. Supercritical ﬂuid technology
is an umbrella term for multiple techniques that use supercritical ﬂuids
in one form or another. The techniques presented most frequently in
literature are CO2 assisted nebulization, supercritical antisolvent tech-
nique and SCF assisted nebulization drying. All of these techniques use
supercritical liquid CO2, mainly because of its low critical temperature
and environmental friendliness (Carpenter et al., 2002; Mawson et al.,
1997; Sellers et al., 2001; Sievers et al., 2001).
Supercritical ﬂuid technology has several advantages and dis-
advantages. The most important advantages are that the APIs are not
exposed to high temperatures and their physical form and surface
morphology can be controlled. However, the high pressure needed for
nebulization can have a negative eﬀect on the activity of biopharma-
ceuticals (Winters et al., 1996). Furthermore, viral inactivation has
been described, and therefore, it might not be a suitable technology for
vaccine production (Dillow et al., 1999). Lastly, organic solvents are
sometimes needed to increase the solubility of the API in the super-
critical ﬂuid. This is environmentally unfriendly and might result in
aggregation as well. It has been shown that the inclusion of DMSO in
the supercritical ﬂuid induces the development of intermolecular β-
sheet aggregation (Winters et al., 1996).
Another new technique that has been used for particle engineering
is particle replication in non-wetting templates (PRINT), also referred to
as ‘micro molding’. Pure API, or API with excipients, is pressed into a
micro-mold. When this micro-mold is removed, particles with the size
and shape of the mold cups are obtained. This results in a powder with a
uniform particle size, shape and surface morphology. It appears suitable
for the pulmonary delivery of biopharmaceuticals as it has been shown
that particles with an MMAD of 3 μm containing 50% bovine DNase
retained their activity (Mack et al., 2012). However, more research
should be performed to ascertain if this is a suitable preparation method
for high dose APIs, not in the least regarding its scalability.
Spray freeze drying has also been used to generate particles in an
inhalable range. However, spray freeze drying results in highly porous
I. Sibum et al. International Journal of Pharmaceutics 548 (2018) 325–336
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particles which increase the total powder volume to be administered
(Wanning et al., 2017). This is unfavourable for high powder doses and
as such this technique is not further discussed in this review.
Further processing of the resulting particles to impart diﬀerent
properties to the powder, such as pelletization, can be performed.
However, in practice this is hardly done. It can be a result of other
downstream processes. For example, powder ﬁlling with a drum ﬁller
may result in pelletization of the powder (Grasmeijer et al., 2017).
5. Formulation of high dose drug-excipient combinations for
pulmonary administration
The extent to which drug particles have to be formulated depends
on the API in question and the dry powder inhaler used. In its most
basic form, formulation only entails comminution of the particles into
the desired size distribution. However, biopharmaceuticals likely need
to be stabilized ﬁrst by the use of excipients, and excipients may also be
needed to attain an acceptable level of dispersion with the DPI that has
been selected for their administration. The extent to which powders
have to be formulated also dictates what kind of technology will be
most suitable for their preparation. For example, if particles only have
to be obtained in the correct particle size distribution, and the API is not
very sensitive to mechanical stress, milling would be ideal as it is a
simple one-step process. However, for many drug-inhaler combinations
simple milling will yield a product that is unsuitable for inhalation.
Much of particle engineering for the drug particles can be done by
simply changing processes or process parameters in techniques such as
spray drying and supercritical ﬂuid drying. In situations where this is
not eﬀective, excipients may oﬀer additional possibilities to obtain the
desired powder properties. Particle engineering by varying the process
conditions or using excipients may for instance be desired for:
• stabilizing biopharmaceuticals and vaccines;
• increasing drug solubility;
• decreasing or increasing (the rate of) moisture uptake;
• targeting macrophages or avoiding clearance by them;
• increasing muco-adhesion;
• adding a delayed or controlled release proﬁle;
• improving the dispersion of the powder.
Although all of these applications are of interest for low dose drugs
as well, some are especially relevant where high dose drugs are con-
cerned. Therefore, they are brieﬂy reviewed and discussed in terms of
their feasibility.
Biopharmaceuticals and vaccines can be stabilized by encapsulation
in amorphous sugar matrices (Hinrichs et al., 2001; Tonnis et al., 2013).
For instance, inulin was used in a ratio of 200:1 (inulin:vaccine) to
produce an inﬂuenza vaccine suitable for pulmonary administration.
One mg of powder of this pulmonary vaccine oﬀered a similar im-
munization as a single I.M. dose in mice (Audouy et al., 2011). Other
common sugar:protein ratios are 5:1 and 10:1. Of course, such a high
fraction of excipient is only feasible if the pure vaccine is potent enough
to prevent an extraordinarily high formulated powder mass for a single
dose. The same is true for cyclodextrins, which may be used to increase
drug solubility (Loftsson, 2002). Mohtar et al. developed a ﬁsetin dry
powder suitable for pulmonary administration. Cyclodextrin was used
in a molar ratio of 2:1 (ﬁsetin:cyclodextrin) to increase the dissolution
rate 8 fold (Mohtar et al., 2017). Fisetin, like all APIs, needs to dissolve
ﬁrst in the lung ﬂuid before it can have its anticancer eﬀect.
L-leucine has been used to decrease the moisture uptake by pow-
ders. Li et al. showed that 10–20% of L-leucine could protect disodium
cromoglycate from moisture induced crystallization and reduce water
sorption by more than half (Li et al., 2016).
In contrast, Tian et al. used excipients to increase water uptake in
excipient enhanced growth formulations. (Tian et al., 2013). This
causes particles to absorb water from the moist air during transport
through the lungs, increasing their size and deposition eﬃciency. In one
of their studies they used 50 or 75% of sodium chloride as hygroscopic
excipient. Particles with an initial geometric diameter of 900 nm in-
creased in size to around 5–6 μm in the lungs, which increased their
lung deposition 20–30-fold when compared to conventional formula-
tions. The high fraction of excipient required for this particular appli-
cation implies that it will only be feasible to administer an excipient
enhanced growth formulation in a single inhalation maneuver for drugs
dosed up to approximately 15–25mg in their pure form.
Vyas et al. produced liposomes with rifampicin, which were tar-
geted to macrophages by the use of O-steroyl amylopectin. With this
formulation the viability of Mycobacterium smegmatis within macro-
phages went down by 28% compared to rifampicin in neutral lipo-
somes, which was attributed to the targeting eﬀect (Vyas et al., 2004).
On the other hand, inclusion of cholesterol or sphingomyelin in lipo-
somes lowers their uptake by macrophages and may prolong their re-
sidence time in the lungs (Patel et al., 2015). A major disadvantage of
working with liposomes is the increase in mass that is to be inhaled for
a full dose. For example, liposomes have been formulated that contain
less than 10% of isoniazid (Rojanarat et al., 2011). Isoniazid is dosed up
to 300mg IM once daily. Assuming that the isoniazid liposomes are just
as eﬀective as an IM bolus, 3 g would have to be inhaled to obtain the
same eﬀect. When a DPI can deliver 50mg of powder in a suitable
particle size distribution per inhalation, at least 60 inhalation man-
euvers would have to be performed. This of course disregards the po-
tentially higher eﬃciency of local and targeted delivery. Furthermore,
multiple inhalation maneuvers might still be preferred over a single
injection.
Nano- or microparticles prepared using biodegradable polymers
have the same disadvantage. For example, Sung et al. produced a ri-
fampicin sustained release formulation by using porous nanoparticle-
aggregate particles (Sung et al., 2009). These PLGA nanoparticles self-
assembled into porous microparticles suitable for inhalation. The
highest ﬁne particle fraction found was 44.7 ± 2.3% and the highest
drug load found was 10.0 ± 0.1%. Therefore, this formulation tech-
nique likely increases the mass and volume of the powder too much to
make it suitable for high dose drugs.
In addition to liposomes, muco-adhesion can also be used to in-
crease the residence time of particles in the lungs after administration
(Fiegel et al., 2004). Lui et al. produced microparticles from hyaluronic
acid (HA) which contained budesonide (BUD) nanocrystals in a ratio of
3.5:1 (HA:BUD). These microparticles showed a signiﬁcantly longer
pharmacological eﬀect in rats compared to an inhaled budesonide
suspension. The microcrystals had a half-life of 12.56 ± 8.39 h while
the nanocrystals had a half-life of 0.98 ± 1.11 h. This longer half-life
for the microcrystals was attributed to the muco-adhesive properties of
hyaluronic acid (Liu et al., 2018). The avoidance of macrophages and
the use of muco-adhesion is especially relevant for formulations with a
delayed or controlled release proﬁle, which may also be achieved by the
use of excipients (Patel et al., 2015).
Finally, improving the dispersibility of inhalation powders is the
most frequently mentioned argument in literature for drug particle (co-)
engineering. Dispersibility of powders may be aﬀected by weakening
the cohesion forces between the particles. As such, any process para-
meter or excipient that modiﬁes the particle surfaces (e.g. roughness,
chemistry, hardness) in a favorable way may potentially improve
powder dispersion. In some instances, the exact mechanism by which
excipients improve dispersion is not clear. For example, co-milling of
only 1% L-leucine with levodopa increased the levodopa ﬁne particle
fraction from the Cyclops dry powder inhaler at 4 kPa from 20 to 30%
for the pure formulation to 60–70% for the blend (Luinstra et al., 2015).
In contrast with co-spray dried L-leucine, co-milled L-leucine seems
unlikely to aﬀect the shape and surface chemistry of the levodopa
particles in the formulation. In other examples much higher excipient
masses are used and/or highly porous particles are produced to reduce
the interparticulate forces and increase the eﬃcacy of the dispersion
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forces. Highly porous particles have relatively large geometric dia-
meters and aerodynamic (e.g. drag) forces can get much better hold of
such particles. Besides, such particles can escape macrophage clearance
(Edwards et al., 1997) and when the porosity is partly external on the
particle surface, they also have reduced contact points with sur-
rounding particles. A very successful example in this respect are the
PulmoSphere™ powders (Dellamary et al., 2000; Geller et al., 2011).
However highly porous particles increase the total powder volume to be
administered in a similar way as large excipient amounts increase the
total powder mass. Therefore, designing and developing more powerful
DPIs seems a better solution for improving dispersion.
Lastly, multi-step processes and excipients used in particle en-
gineering may result in expensive formulations whereas some processes
seem hardly eﬃcient. For example, in liposome production encapsula-
tion eﬃciency can be rather low for some APIs, as Table 2 illustrates.
All these formulation aspects limit the usefulness of these formulations
in practice for high dosed drugs. The use of excipients may also in-
troduce certain health risks. Even for endogenous compounds that are
‘generally regarded as safe’ it may not always be clear what their eﬀect
with prolonged pulmonary administration (as with TB treatment) will
be. Disturbing the physiological concentration of such substances in the
long term may also disturb the processes in which they play a role.
6. DPI design for high powder doses
In the previous sections some diﬀerences in properties and behavior
between adhesive mixtures for low dose drugs and high dose cohesive
powder masses have been explained. They provide the basis for the
design of DPIs for the pulmonary delivery of high powder doses. It has
also been explained why using excipients in formulations for high dose
drugs should preferably be avoided, particularly when they sub-
stantially increase the inhaled powder quantity and, by that, the
number of inhalations needed to administer a single dose. Refraining
from the use of such dispersion enhancing excipients may result in ra-
ther cohesive powders, but this may not be a problem when more ef-
fective dry powder dispersion principles for such formulations are de-
signed and developed. Only to achieve special therapeutic eﬀects or to
improve the stability of the formulation, co-formulation with excipients
may be inevitable.
Fig. 2 shows the basic design of a DPI. It consists of at least three
primary functional parts, the powder formulation with the drug, a
powder compartment to contain or measure the amount of formulation
for a single drug dose and a dispersion principle for the powder for-
mulation. In the Sections 2–5 the powder preparation and formulation
techniques, as well as the most relevant properties of diﬀerent powders
were already discussed. From the discussions it may have become clear
that various inhaler parts have to be compatible with the properties of
the drug formulation. This is the reason why separate development of
formulation and device is unlikely to yield a fully optimized combina-
tion.
From the viewpoint of consistency of delivered dose, the dose
(measuring) compartment for high cohesive powder doses is of utmost
importance. Several DPIs for delivery of adhesive mixtures have large
powder compartments with various volumetric measuring principles for
the isolation of single doses from the bulk supply (Fig. 3A). The me-
tering principle has to be operated by the patient and the inhaler has to
be kept in the correct position for gravimetric ﬁlling of the measuring
compartment, which is generally a cavity in a slide or a cylinder ad-
jacent to the large powder compartment. This requires good ﬂow
properties of the formulation. However, pure micronized powders are
rarely well ﬂowing.
Agglomerates (spherical pellets) can be prepared to solve this pro-
blem but they are physically instable as they need to be soft to enable
eﬀective dispersion during inhalation. Storing them in large containers
bears the risk that they will break or clump together when the DPI is
exposed to vibration or shaking (as for instance during running) or
dropping (Hoppentocht et al., 2014a). This risk increases with in-
creasing powder mass and volume of the storage container. Pre-loaded
compartments for single doses are a better solution for high dose mi-
cronized powders. Pelletization may be necessary to ﬁll such com-
partments accurately and reproducibly, but once in the compartment
any break down or lumping together of the pellets will no longer aﬀect
the dose measuring and consistency of delivered dose. Single dose
compartments are also used for adhesive mixtures in capsule and blister
inhalers but these types of dose containers may not be the best choice
for high doses of cohesive powders. Capsules generally need high ﬂow
rates for complete discharge of their contents through the narrow holes
and/or slits obtained from perforating their ends in the relatively short
time of inhalation. Besides, both hard gelatin and hydroxypropyl me-
thylcellulose (HPMC) capsules frequently fragment in the violent air
stream, thereby releasing inhalable fragments. Single dose cartridges
(SDC) seem a better solution because they potentially provide better
protection of the drug formulation against moisture uptake and do not
fragment during inhalation. Peelable lidding foils will be needed for
cohesive high dose powder masses to uncover the entire SDC surface
because piercing will create small shreds of lidding foil that stick be-
yond the surface around the discharge hole (Fig. 3B). These shreds will
press the particles sideward and become an obstacle in the exit route for
the cohesive powder. Completely opened SDCs have another major
advantage. They enable to direct the air stream through the SDC via
separate inlet and exit channels (Fig. 3C). This improves the eﬃcacy of
the entrainment of cohesive powder agglomerates and also shortens the
discharge time.
The dispersion principle is the engine of the inhaler that converts
the cohesive powder mass into an appropriate aerosol for inhalation. It
derives external forces from the ﬂuid energy to overcome the inter-
particulate attraction forces in the powder during inhalation. The dis-
perser has to be designed to fulﬁll the basic requirements for eﬀective
aerosol deposition in the human respiratory tract, which have been
described extensively elsewhere (Demoly et al., 2014). These require-
ments are basically the same for low and high dose DPIs but they may
depend on the type of therapy and hence, the preferred site of de-
position for the aerosol particles. They may also be diﬀerent for dif-
ferent patient groups (Lexmond et al., 2017). The basic requirements
for eﬀective aerosol deposition are brieﬂy summarized in Table 3.
Particularly prerequisite 3 in Table 3 has long been misinterpreted. A
higher ﬁne particle fraction, and/or a ﬁner aerosol at a higher ﬂow rate
are needed to compensate (at least partly) for the shift in deposition
towards larger airways, including the mouth-throat region (Demoly
et al., 2014). This more or less excludes the use of battery or pressurized
air powered dispersion which is independent of the inhalation man-
euver. Auxiliary energy sources for dispersion have previously been
applied for instance in the Spiros and Exubera DPIs (Harper et al., 2007;
Licalsi et al., 1999). Such complex inhalers are also unwanted because
of the cost aspect. To achieve the prerequisites in Table 3, diﬀerent
dispersion principles may be optimal for diﬀerent powder formulations.
Air classiﬁer technology has previously been presented as the most
eﬀective technology for dispersion of adhesive mixtures (De Boer et al.,
2003). Air classiﬁers and other circulation chambers generate inertial
Table 2
Several APIs that have been formulated into liposomes in literature and their
reported entrapment eﬃciency. References included: (Bai and Ahsan, 2009;
Bhardwaj et al., 2012; Chougule et al., 2007; Shah and Misra, 2004).
API included in liposomes Reported entrapment eﬃciency (%)
Amphotericin B 43.9 ± 2.4 to 95.8 ± 1.5
Tacrolimus 97 ± 0.4 to 98 ± 1.4
Rifampicin 43.08 ± 4.6
Isoniazid 18 ± 1 to 39.67 ± 1.5
Pyrazinamide 39.33 ± 8.1
Low molecular weight heparin 41
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separation forces which are proportional to the third power of the
particle diameter. In comparison, drag and lift forces, as in turbulent air
streams, are proportional to the ﬁrst power of the particle diameter (in
the Stokes’ regime). Because of their good ﬂow and aerosolization
properties, carrier-based formulations are mostly equally distributed
over the entire circulation chamber for the powder in an air classiﬁer-
based dispersion principle. This is diﬀerent for cohesive powders. They
mostly enter circulation chambers as a lump of powder from the dose
compartment. This can disturb the ﬂow symmetry in that chamber and
thereby its dispersion eﬃcacy. Moreover, cohesive powders are also
adhesive and tend to stick to the chamber wall upon collision with that
wall. As a result, thick powder layers may be formed and they reduce
the emitted dose considerably. Retention within the circulation
chamber can to reasonable extent be controlled by adding so-called
sweeper crystals to the micronized powder (de Boer et al., 2006). Such
Fig. 2. Schematic representation of a high dose dry powder inhaler. Shown are the functional parts of which the powder formulation, dose (measuring) compartment
and dispersion principle need to be a compatible combination.
Fig. 3. (A) Powder container with dose measuring
cylinder for powders with suﬃcient ﬂow properties
to enable volumetric ﬁlling by the force of gravity.
(B) Pre-measured blister with pierced lidding foil,
showing the patches of foil that protrude into the
dose cavity around the discharge hole and hinder the
powder to be entrained by the inhaled air stream.
The risk of incomplete blister emptying becomes
greater with deteriorating ﬂow properties of the
powder. (C) Blister with peelable lidding foil.
Opening the entire blister surface provides the pos-
sibility to conduct (at least part of) the air stream
through the blister for improved powder entrain-
ment.
Table 3
General prerequisites for eﬀective aerosol delivery to the human respiratory
tract with dry powder inhalers (the same for high and low doses).
1. aerosol delivery at a low inhaled ﬂow rate, preferably in the range between 30 and
50 L/min, to avoid high oropharyngeal deposition
2. delivery of the fast majority of the aerosol mass in the ﬁrst 0.5–1.5 L of inhaled air
(VIN). The exact volume of VIN varies with the patient population and depends on
their vital capacity
3. delivery of a higher ﬁne particle mass and/or a higher ﬁneness of the aerosol at a
higher ﬂow rate to compensate (at least partly) for the shift in deposition towards
larger airways, including the oropharynx
4. delivery of an aerosol within the preferred aerodynamic size range of 1–3 µm*
* Inhalation aerosols should not be deﬁned with their mass median aero-
dynamic diameter (MMAD) as this gives no information about the mass fraction
of the dose within the preferred size range.
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crystals can be lactose crystals, similar to the carrier crystals in adhesive
mixtures. They circulate in the chamber and wipe adhering drug par-
ticles from the cylindrical chamber walls during inhalation. Usually
they are larger than the theoretical cutoﬀ value of the classiﬁer
chamber as a result of which they are not inhaled by the patient. An-
other approach to tackle this problem of high classiﬁer retention is to
interrupt its cylindrical wall with a number of tangential bypass
channels (Fig. 4A). Such channels support the circular ﬂow in the
chamber and increase the contribution of the mechanism of shear ﬂow
to the powder dispersion (Fig. 4B).
One limitation of air classiﬁers is their limited volume. Their design
is aimed at ﬁnding the optimal dispersion eﬃcacy for the powder mass
to be administered. This generally includes the smallest possible cir-
culation chamber for that powder mass yielding the highest air (and
particle) velocity inside the chamber and, thus, the highest separation
forces. A larger chamber can contain a larger powder mass but has a
lower dispersion eﬃcacy. This is due to a much lower air velocity at the
same ﬂow rate, which preferably should not exceed 30–50 L/min
(Table 3). A smaller chamber for the same powder mass results in
overloading: particles will crowd each other out by uncontrolled col-
lisions, even if they are still much larger than the theoretical cutoﬀ
value. A solution for this problem can be a gradual feeding of the
classiﬁer from the dose compartment in order to ﬁnd a good equili-
brium between classiﬁer feed and discharge rate. This will result in a
fairly constant classiﬁer load. Finding a good balance between feed and
discharge rate may be diﬃcult however, and it may depend on the type
of formulation. Dispersion of cohesive powders can follow diﬀerent
regimens, requiring diﬀerent time spans. Particularly when the dis-
persion rate is initially high, high mass fractions of ﬁne particles are
generated and the particles can leave the classiﬁer instantaneously
when their diameter is smaller than the cut-oﬀ diameter of the classi-
ﬁer. According to this regimen, discharge time can be very short. Dis-
persion may also be a more staggered process and large agglomerates
may stepwise break into smaller particles. This takes more time to
discharge the total dose and the feed rate of the classiﬁer must be lower.
This example emphasizes the need for joint design and development of
formulation and device as it shows how diﬃcult ﬁne tuning can be for
achieving the best possible performance of the combination.
An optimum classiﬁer feed rate exists also in another respect. If the
feed rate to the disperser principle is too low not all powder will be
delivered to the patient or be transported to the lower airways in the
total inhalation time. For this to happen the powder generally has to be
dispersed in the ﬁrst 1.5 L of air (Table 3) (Hoppentocht et al., 2014a).
For speciﬁc patient groups such as children this may even be within the
ﬁrst 0.5 L of air (Lexmond et al., 2017). A similar problem may arise in
classic capsule inhalers. Whereas a capsule can contain 150mg of
powder, it is diﬃcult to disperse this or even a fraction of this amount
of powder during one inhalation. Thus, it often requires multiple in-
halation maneuvers to empty the capsule (Hoppentocht et al., 2014a).
The need for multiple inhalation maneuvers reduces the motivation of
patients to follow the inhalation instruction and to adhere to the
therapy. Therefore, the number of inhalations required should be
minimized. Especially for the delivery of antibiotics adherence and
compliance are two major challenges. As Newman et al. showed, poor
inhaler use can result in poor adherence and even more serious, treat-
ment failure (Newman and Busse, 2002).
Aerodynamic dispersion principles may be appropriate for the dis-
persion of large cohesive powder doses too. They ﬁnd wide application
in the dispersion of powders for particle size analysis and various in-
dustrial processes. They rely mainly on rapid acceleration or decel-
eration of particle agglomerates, shear ﬂow, particle-particle collisions,
or a combination of these mechanisms. Examples are eductors, venturis,
nozzles and capillary tubes (Calvert et al., 2009). Standard versions of
these principles are normally operated at high ﬂow rates, requiring
much higher pressure drops (in the range of several bars) than patients
can generate. Therefore, special designs are needed to serve adequately
as disperser for high powder doses meant for inhalation. They are an
interesting option however, as they are relatively simple and exploring
the possibilities with such principles seems worthwhile.
Several additional inhaler aspects or requirements may be the same
for inhalers that contain adhesive mixtures or large cohesive powder
masses and yet be much more meaningful or necessary for high cohe-
sive powder doses. For instance, in the treatment of infectious diseases
the minimum inhibitory concentration (MIC) of the inhaled antibiotic
needs to be achieved at all places where the pathogenic bacteria are
present. At places where the antibiotic concentration remains con-
sistently below the MIC-value, resistance development of the bacteria
against the antibiotic may occur. From currently marketed dry powder
inhalers approximately one third of the inhaled aerosol is deposited in
the upper airways, one third in the central and one third in the re-
spiratory airways. Considering the exponential increase in lung volume
and surface area from the lobar bronchi towards the alveoli, this may
result in an extreme decrease in drug concentration by a factor 100 or
more over the entire respiratory tract (Demoly et al., 2014). A
Fig. 4. Diﬀerent designs of an air classiﬁer as dis-
persion principle for inhalation powders. (A) Basic
concept of a disk-shaped circulation chamber with
two opposite air supply channels designed for the
dispersion of (low dose) adhesive mixtures primarily.
Freely, non-sticking carrier particles circulate along
the circumference of the chamber and collide with its
cylindrical wall and with each other generating in-
ertial forces for the detachment of drug particles
from the carrier surface. (B) Classiﬁer with a multi-
tude of bypass channels for the dispersion of cohe-
sive (sticky) powders. In the area in front of a bypass
channel the impinging air ﬂows create internal shear
in agglomerates, which results in disruption of the
agglomerates (C). The air stream from the bypass
channel also keeps primary drug particles away from
the remainder of the cylindrical chamber wall.
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signiﬁcant improvement in peripheral deposition at the cost of central
and upper tract deposition does not even change the decrease in con-
centration much. This bears the risk of serious underdosing of the
lowest airways and for this reason the aerodynamic size distribution of
the delivered aerosol and the inspiratory ﬂow maneuver with which the
aerosol is inhaled are of utmost importance. Many high dose drugs are
also considerably more hygroscopic than low dose drugs against asthma
and COPD. Antibiotics like tobramycin sulfate can absorb suﬃcient
water from the air at a high relative humidity (above approx. 65%) to
dissolve completely and merge from particles into droplets
(Hoppentocht et al., 2015). Also, amorphous sugars used to stabilize
large biopharmaceutical molecules in the dry state are extremely hy-
groscopic. This requires not only good moisture protection of the
powder formulation in the dose compartment but also advocates the
use of disposable inhalers for such drugs. Small drug residues in dry
powder inhalers after use are inevitable and when such inhalers are
exposed to the ambient air, liquefying of the residual particles may
make following inhalations with the same device impossible. Because of
the high drug doses involved the number of residual particles will be
rather extreme. Even for a relatively low retention of 5%, the drug mass
retained from a single 50mg dose is 2.5 mg. This amount of drug is
suﬃcient to form relatively large droplets upon water sorption in the
passageways for the powder. Therefore, from the viewpoint of eﬃcacy
and safety, hygroscopic cohesive powders should preferably be ad-
ministered with disposable devices.
Other high powder dose applications that could beneﬁt from a
disposable inhaler are all one time use medications, such as vaccina-
tions and rescue medication, or the short-term treatment of infections in
hospitals (de Boer and Hagedoorn, 2015; Friebel and Steckel, 2010).
Although disposable inhalers can be more expensive than reusable
ones, they are not necessarily increasing the cost of the therapy, be-
cause a more eﬀective treatment can save much higher costs in the long
term, e.g. those from hospitalization.
One aspect of consideration for the use of disposable medical de-
vices is the environmental burden. For the inhalation of antibiotics,
which are currently mostly nebulized, the choice is either between a
disposable plastic DPI or two disposable (plastic or glass) vials for the
drug and sterile water respectively, plus a syringe with needle, or a
special dispensing pin. In either case, it has to be recommended that
used devices and materials polluted with drug residues or containing
needles, are collected and transferred to a special recycling depot. Many
DPIs are made of a medical grade of polycarbonate, which is diﬃcult to
reuse and received recycling code 7 for that. However, the inhaler can
be made of plastic only, whereas for nebulization diﬀerent waste ma-
terials are produced which makes recycling even more complex and
expensive. Besides, recent research has improved the possibilities for
recycling of polycarbonate waste material considerably (Datta and
Kopczyńska, 2016).
Another consideration of interest for disposable inhalers is the cost
of the therapy. Although they can be more expensive than re-usable
ones, it is often the price of the API that determines the cost of the drug-
device combination. Besides, disposable inhalers can be very simple
(Fig. 5A and B) and yet highly eﬀective (next section) if designed ap-
propriately. Their use can eliminate several risks, such as improper
functioning due to liquefying of drug residues after moisture uptake,
patient cross-contamination, etc. (de Boer and Hagedoorn, 2015).
7. Currently available high dose DPIs
High dose inhalers described in literature are the Podhaler®, the
Turbospin®, the Orbital®, the FB-DPI, the Twincer® and the Cyclops®.
They are depicted in Fig. 5. Other high dose inhalers with little to no
published information about their performance are the Powdair, the
ICOone™ and the Twincaps®, which for that reason will not be discussed
further.
The Podhaler® (T-326, Fig. 2A) is the original Turbospin® capsule
inhaler and used for the TOBI® Podhaler® product from Novartis AG. It
is used with the previously mentioned highly dispersible engineered
particles using the PulmoSphere™ technology, with a capsule con-
taining 28mg of the drug tobramycin. The capsule with approx. 55mg
of powder (including excipients) is emptied in a single inhalation
maneuver. However, in practice patients are instructed to perform a
second inhalation maneuver to ensure suﬃcient emptying. Total dose is
4 capsules, or 112mg of tobramycin. The capsule load of 28mg to-
bramycin was based on the ability of 6–10 year old patients to empty
the capsule, and a higher load is likely achievable in adults (Geller
et al., 2011). In this product the formulation is adapted to the inhaler,
and it is likely that a more eﬃcient and better accepted product is
possible when the inhaler is adapted to tobramycin, with a stronger
dispersion system lowering the need for excipients. Furthermore, the
dose system could be more eﬃcient when a preﬁlled compartment is
used instead of a capsule. This would likely lower the amount of in-
halation maneuvers needed and increase the compliance and adherence
to therapy.
A smaller version of the Turbospin® capsule inhaler is used in the
Colobreathe® product (Fig. 2B). Its capsules contain approximately
145mg of colistimethate sodium without excipients, of which 125mg is
emitted. A dose comprises a single capsule (Schuster et al., 2013). Pa-
tients have to repeat inhalation maneuvres until the capsule is empty
(European Medicines Agency, 2018). This device would beneﬁt from
the same improvements as the Podhaler®, i.e. a dose compartment in-
stead of a capsule and a more powerful dispersion principle.
The Orbital® (Fig. 2C) dry powder inhaler is an inhaler currently
under development by Pharmaxis Ltd. It is able to dose 50mg to several
hundreds of milligrams by multiple inhalation maneuvers (Young et al.,
2013; Zhu et al., 2015). It is a disposable DPI and the dose is kept in a
single dosing puck. The dose delivered during each individual inhala-
tion is a result of the airﬂow through the device and the geometry of the
dose compartment and that of the puck itself. They demonstrated the
ability to dose 400mg of mannitol in a single inhaler, but with multiple
inhalations (Zhu et al., 2015). Discharge and dispersion is a result of the
rotation of the puck. The device is disposable and comes with a preﬁlled
dose compartment, which makes it suitable for the delivery of high
doses. However, the need for repeated inhalation maneuvers could
lower the compliance and adherence to therapy.
The FB-DPI (Fig. 2D), described by Farkas et al. is based on the ﬂuid
bed principle for dispersion. In the inhaler small spheres are placed that
have a ﬂuid-like behavior during inhalation. This random motion of the
small spheres causes turbulence and collisions, which will disperse
powder as it passes through it. They reported that they were able to
disperse 100mg of powder eﬃciently from the inhaler and the for-
mulation they used contained 20% leucine, which is known to aid
dispersion. Furthermore, they reported that the removal of the small
spheres did not have a negative eﬀect on the ﬁne particle fraction while
increasing the emitted dose (Farkas et al., 2015). As a result, questions
can be raised on the eﬃcacy of the dispersion principle used. The de-
vice does use a preﬁlled dose compartment instead of a capsule.
However, it is unclear how well the dose compartment protects the
formulation from moisture, what the maximum dispersible dose is and
how many inhalations are required to administer this dose.
The Twincer® (Fig. 2E) and Cyclops® (Fig. 2F) are both disposable
devices developed at the University of Groningen (de Boer et al., 2006;
Hoppentocht et al., 2015). Both use the air classiﬁer technology for
dispersion, which is based on inertial forces. Optimized for diﬀerent
formulations, the Twincer® is currently prescribed on the bases of
medical necessity in cystic ﬁbrosis patients for the delivery of 55mg of
milled colistimethate sodium, without the need for excipients
(Hagedoorn et al., 2017). The Cyclops® device is optimized for the
delivery of pure tobramycin, and is able to dose up to at least 50mg is
one single inhalation maneuver with a ﬁne particle fraction of> 90%
of the delivered dose (Hoppentocht et al., 2015). With the minimal use
of excipients (2% L-leucine) also levodopa, with a dose up to 40mg, has
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been successfully formulated for this device (Luinstra et al., 2015). Both
devices use a pre-ﬁlled dose compartment and are able to administer
the dose in one inhalation maneuver.
8. Conclusions
In this review we have deﬁned high powder doses for pulmonary
administration as all powders that contain more than 2.5mg of active
inhalable microparticles with or without excipient. Following this de-
ﬁnition, drugs with a low potency such as antibiotics and drugs with a
high potency that need a substantial fraction of excipient(s), such as
vaccines stabilized in sugar glasses, are all considered ‘high dose drugs’.
For high dose drugs one cannot rely on adhesive mixtures to solve many
of the challenges brought about by the high co- and adhesiveness as-
sociated with the micronized state of the particles. For many low po-
tency drugs one can neither rely on large fractions of excipient to
overcome these challenges, as they would increase the powder mass or
volumes to be administered to amounts that either require too many
inhalation maneuvers when splitting them up, or are intolerable to the
patient when taken at once. Therefore, we strongly advocate an ap-
proach in which high dose DPIs and their formulations are developed in
unison in order to adapt the DPI design and performance to the prop-
erties of the drug formulation. Techniques such as spray drying and
supercritical ﬂuid drying enable considerable rational particle en-
gineering with little to no excipients. For that reason, they should be the
starting point of any formulation endeavors when more complex and
elaborate formulations are not required from a therapeutic perspective.
We envisage that the most optimal dry powder inhaler to disperse high
dose formulations contains a pre-loaded dose container with a peelable
lidding foil, is disposable and cheap, intuitive in use and contains an
eﬀective dispersion principle. Eﬀective dispersion of high dose powders
may not always be achieved with dispersion principles relying on what
are generally considered the most eﬀective (i.e. inertial) dispersion
forces. High dose powders are often highly compactable and relying on
collisions with the inhaler walls for dispersion may, therefore, result in
considerable retention of the formulation within the inhaler. Great
opportunities to make a diﬀerence with the pulmonary administration
of high powder doses are awaiting to be explored. We strongly believe
that the knowledge required for the successful development of high
dose dry powder inhalation products is readily available. Therefore, it is
only a matter of taking the right approach to make these great oppor-
tunities into great successes.
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